BioNTech SE
BNTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, BioNTech SE (BNTX) is listed under Biotechnology. Valued at $23.13B, BNTX is a large-cap name in its sector. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Market Cap
$23.13B
Beta
1.32
P/E (TTM)
—
P/E (Fwd)
-18.47
EPS (TTM)
$-5.77
EPS (Fwd)
$-4.95
ROE
-6.7%
ROA
-4.2%
Cash
$13.71B
Total Debt
$302.8M
Free CF
-$428.1M
52W Change
-16.9%
Annual Financials
Cash vs Debt
BioNTech SE holds $13.71B in cash against $302.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$428.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -6.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $17.31B (2022) to $2.87B (2025), a 83% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BioNTech SE and its sector.